2021
P10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. P10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE. Leukemia Research 2021, 108: 106681.10. DOI: 10.1016/j.leukres.2021.106681.10.Peer-Reviewed Original Research
2015
Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies
Zeidan A. Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies. International Journal Of Hematologic Oncology 2015, 4: 215-217. DOI: 10.2217/ijh.15.25.Peer-Reviewed Original ResearchMyelodysplastic syndromeHematologic malignanciesNovel therapiesYale Cancer CenterReal-life effectivenessMyeloid hematologic malignanciesHematology/oncology fellowshipRochester General HospitalInternal medicine residencyCancer CenterClinical trialsGeneral HospitalClinical investigationFaculty of MedicineOncology fellowshipsMalignancyTherapyClinical interestTranslational researchMedicine residencyOutcomes researchMBBS degreeMedicineJohns Hopkins UniversityResearch Fellowship